Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal

被引:15
|
作者
Meisel, Andreas [1 ]
Baggi, Fulvio [2 ]
Behin, Anthony [3 ]
Evoli, Amelia [4 ,5 ]
Kostera-Pruszczyk, Anna [6 ]
Mantegazza, Renato [2 ]
Morales, Raul Juntas [7 ]
Punga, Anna Rostedt [8 ]
Sacconi, Sabrina [9 ]
Schroeter, Michael [10 ]
Verschuuren, Jan [11 ]
Crathorne, Louise [12 ]
Holmes, Kris [12 ]
Leite, Maria-Isabel [13 ]
机构
[1] Charite Univ Med Berlin, NeuroCure Clin Res Ctr, Integrated Myasthenia Gravis Ctr, Dept Neurol, Berlin, Germany
[2] Fdn Carlo Besta Neurol Inst, Neuroimmunol & Neuromuscular Dis Unit, Sci Inst Res & Hlth Care, Milan, Italy
[3] Hop La Pitie Salpetriere, Publ Hosp Network Paris, Inst Myol, Dept Neuromyol, Paris, France
[4] Univ Cattolica Sacro Cuore, Rome, Italy
[5] Agostino Gemelli Univ Polyclin Fdn, Sci Inst Res & Hlth Care, Rome, Italy
[6] Med Univ Warsaw, Dept Neurol, Warsaw, Poland
[7] Vall dHebron Univ Hosp, Neurol Dept, Barcelona, Spain
[8] Uppsala Univ, Dept Med Sci, Clin Neurophysiol, Uppsala, Sweden
[9] Nice Univ Hosp Ctr, Nice, France
[10] Univ Hosp Cologne, Dept Neurol, Cologne, Germany
[11] Leiden Univ, Med Ctr, Neurol, Leiden, Netherlands
[12] Prescript Commun, Letchworth, England
[13] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England
关键词
autoantibodies; biomarkers; myasthenia gravis; ANTIACETYLCHOLINE RECEPTOR ANTIBODY; ACETYLCHOLINE-RECEPTOR; DISEASE SEVERITY; TITIN-ANTIBODIES; PROTEIN; MUSK; ASSOCIATION;
D O I
10.1111/ene.15565
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose Although myasthenia gravis (MG) is recognized as an immunoglobulin G autoantibody-mediated disease, the relationship between autoantibody levels and disease activity in MG is unclear. We sought to evaluate this landscape through systematically assessing the evidence, testing the impact of predefined variables on any relationship, and augmenting with expert opinion. Methods In October 2020, a forum of leading clinicians and researchers in neurology from across Europe (Expert Forum for Rare Autoantibodies in Neurology in Myasthenia Gravis) participated in a series of virtual meetings that took place alongside the conduct of a systematic literature review (SLR). Results Forty-two studies were identified meeting inclusion criteria. Of these, 10 reported some correlation between a patient's autoantibody level and disease severity. Generally, decreased autoantibody levels (acetylcholine receptor, muscle-specific kinase, and titin) were positively and significantly correlated with improvements in disease severity (Quantitative Myasthenia Gravis score, Myasthenia Gravis Composite score, Myasthenia Gravis Activities of Daily Living score, Myasthenia Gravis Foundation of America classification). Given the limited evidence, testing the impact of predefined variables was not feasible. Conclusions This first SLR to assess whether a correlation exists between autoantibody levels and disease activity in patients with MG has indicated a potential positive correlation, which could have clinical implications in guiding treatment decisions. However, in light of the limited and variable evidence, we cannot currently recommend routine clinical use of autoantibody level testing in this context. For now, patient's characteristics, clinical disease course, and laboratory data (e.g., autoantibody status, thymus histology) should inform management, alongside patient-reported outcomes. We highlight the need for future studies to reach more definitive conclusions on this relationship.
引用
收藏
页码:266 / 282
页数:17
相关论文
共 50 条
  • [21] Methotrexate in generalized myasthenia gravis: a systematic review
    Prado, Mario B.
    Adiao, Karen Joy B.
    ACTA NEUROLOGICA BELGICA, 2023, 123 (05) : 1679 - 1691
  • [22] Economic Costs of Myasthenia Gravis: A Systematic Review
    Landfeldt, Eri
    Pogoryelova, Oksana
    Sejersen, Thomas
    Zethraeus, Niklas
    Breiner, Ari
    Lochmueller, Hanns
    PHARMACOECONOMICS, 2020, 38 (07) : 715 - 728
  • [23] A systematic review of diagnostic studies in myasthenia gravis
    Benatar, Michael
    NEUROMUSCULAR DISORDERS, 2006, 16 (07) : 459 - 467
  • [24] RITUXIMAB TREATMENT OF MYASTHENIA GRAVIS: A SYSTEMATIC REVIEW
    Tandan, Rup
    Hehir, Michael K., II
    Waheed, Waqar
    Howard, Diantha B.
    MUSCLE & NERVE, 2017, 56 (02) : 185 - 196
  • [25] Economic Costs of Myasthenia Gravis: A Systematic Review
    Erik Landfeldt
    Oksana Pogoryelova
    Thomas Sejersen
    Niklas Zethraeus
    Ari Breiner
    Hanns Lochmüller
    PharmacoEconomics, 2020, 38 : 715 - 728
  • [26] Course and prognosis of myasthenia gravis: a systematic review
    Mao, Z. -F.
    Mo, X. -A.
    Qin, C.
    Lai, Y. -R.
    Hartman, T. C. Olde
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (07) : 913 - 921
  • [27] The Incidence of Myasthenia Gravis: A Systematic Literature Review
    McGrogan, Anita
    Sneddon, Samantha
    de Vries, Corinne S.
    NEUROEPIDEMIOLOGY, 2010, 34 (03) : 171 - 183
  • [28] Methotrexate in generalized myasthenia gravis: a systematic review
    Mario B. Prado
    Karen Joy B. Adiao
    Acta Neurologica Belgica, 2023, 123 : 1679 - 1691
  • [29] Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic review and meta-analysis
    Tang, Mingbo
    Shao, Yifeng
    Dong, Junxue
    Gao, Xinliang
    Wei, Shixiong
    Ma, Jianzun
    Hong, Yang
    Li, Zhiqin
    Bi, Taiyu
    Yin, Yipeng
    Zhang, Wenyu
    Liu, Wei
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] The role of thymectomy in myasthenia gravis: A programmatic approach to thymectomy and perioperative management of myasthenia gravis
    AL-Bulushi, Ahmed
    Al Salmi, Issa
    Al Rahbi, Fatma
    Al Farsi, AbdulAziz
    Hannawi, Suad
    ASIAN JOURNAL OF SURGERY, 2021, 44 (06) : 819 - 828